CME

Faculty: Neeraj Agarwal, MD, FASCO

Faculty: Rana McKay, MD

This podcast explores the evolving role of molecular profiling and biomarker testing in metastatic castration-sensitive prostate cancer (mCSPC). Drs. Neeraj Agarwal and Rana McKay discuss the clinical significance of PTEN loss and other genomic alterations, their prognostic implications, and how they may inform treatment selection. The conversation reviews emerging data on targeted therapeutic strategies and the integration of precision medicine earlier in the disease course. Practical considerations for incorporating biomarker assessment into clinical decision-making are also examined.

Faculty: Lina Badimón, MD, PhD

Faculty: Michelle O’Donoghue, MD, MPH

Faculty: Erin Michos, MD, MHS

Faculty: Pam R. Taub, MD

A new modular CME-accredited program designed to support clinicians in translating evolving lipid guidelines into everyday practice. Delivered as a 60-minute webcast, divided into chapters for convenience, it integrates U.S. and international perspectives and focuses on equitable cardiovascular care. The course highlights women-specific cardiovascular risk modifiers, including reproductive and hormonal factors that are often under-recognized in risk assessment. It also emphasizes practical, multidisciplinary approaches to improving lipid management outcomes across diverse health systems.

To learn more about Women As One, please click here for additional information.

Faculty: Jorge Plutzky, MD

Faculty: Bradley Eilerman, MD, MHI

With our current understanding of how prevalent hypercortisolism is in patients with difficult-to-manage cardiometabolic disease, the focus shifts to what might clinicians do differently in practice? Which patients should healthcare providers screen, and what straightforward testing methods can be used to detect and confirm hypercortisolism with confidence? Once identified, how might earlier intervention alter the course of disease progression?

Faculty: Muthiah Vaduganathan, MD, MPH

Faculty: Koichiro Kinugawa, MD

Faculty: Michael Böhm, MD

In this panel discussion from the ESC Heart Failure Congress 2026, Drs. Muthu Vaduganathan, Michael Böhm, and Koichiro Kinugawa discuss the role of nonsteroidal MRAs in patients with HFmrEF and HFpEF. Using a clinical case, the faculty review evolving recommendations supporting finerenone as part of guideline-directed medical therapy, along with evidence from FINEARTS-HF and related analyses. The discussion highlights considerations for early initiation, use in combination with SGLT2 inhibitors, patient selection, dosing and monitoring, and management of potassium and renal function changes in clinical practice.

Faculty: Alireza Atri, MD, PhD

Faculty: Raymond Scott Turner, MD, PhD

Faculty: Dani Cabral, MD

In this activity, Dr. Alireza Atri and Dr. Scott Turner discuss the evolving role of subcutaneous anti-amyloid monoclonal antibody therapy in early Alzheimer disease. The conversation compares intravenous and subcutaneous administration and focuses on maintenance dosing after 18 months of IV therapy, practical implications for patients and care partners, and the potential impact on infusion-center burden and treatment access. Dr. Dani Cabral then speaks with a patient living with Alzheimer’s disease, who shares his perspective on using the subcutaneous formulation in the broader context of disease-modifying treatment and long-term management.

Faculty: Sayna Norouzi, MD

In this Patient-Clinician Connection, Dr. Sayna Norouzi discusses shared decision-making approaches for adult patients with C3 glomerulonephritis (C3GN) receiving complement-targeted therapies. Through a clinical patient vignette, Dr. Norouzi demonstrates patient-centered communication techniques for discussing mechanisms, treatment considerations, and long-term kidney preservation goals in clear, accessible language. Dr. Norouzi reviews key differences among treatment approaches, including mechanism of action, proteinuria reduction, kidney function stabilization, monitoring requirements, route of administration, adherence considerations, and infection risk. The activity also highlights the importance of vaccination review, ongoing monitoring, and aligning treatment decisions with patient priorities and lifestyle factors to support collaborative care planning and patient engagement in C3GN management.

Chair: Iacopo Olivotto

Faculty: Elena Arbelo

Faculty: Silvia Aguiar

Did you miss our symposium at ESC HF 2026? It’s not too late! This CME-accredited broadcast replay focuses on improving the diagnosis and management of obstructive hypertrophic cardiomyopathy (oHCM). Learn how to distinguish oHCM from heart failure and how cardiac myosin inhibitors can optimize patient outcomes. Join us and gain valuable tips on applying these insights in practice.

For more information please visit the Heart Failure Congress 2026 website.

Faculty: Scott T. Tagawa, MD, MS

Faculty: Mary-Ellen Taplin, MD

This activity explores current approaches to treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC), including androgen deprivation therapy (ADT), androgen receptor pathway inhibitors (ARPIs), chemotherapy, and emerging targeted therapies. Drs. Scott Tagawa and Mary-Ellen Taplin discuss how disease volume, metastatic distribution, comorbidities, and patient goals inform individualized treatment selection. The program reviews key clinical trial evidence, the evolving role of germline and somatic testing, PTEN loss and AKT pathway targeting, and multidisciplinary strategies to manage adverse events and support quality of life during therapy.

*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

Faculty: Susan L Samson, MD, PhD, FRCPC, FACE

Faculty: Lawrence Blonde, MD, FACP, FACE

Updated diabetes guidelines now recognize a new “other” category of diabetes linked to excess cortisol. This classification reflects emerging prevalence data showing that hypercortisolism may play a much larger role in diabetes development than previously understood. Let’s explore what these new guidelines mean and how they could influence clinical practice.

Faculty: Scott T. Tagawa, MD, MS

Faculty: Mary-Ellen Taplin, MD

This activity explores current approaches to treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC), including androgen deprivation therapy (ADT), androgen receptor pathway inhibitors (ARPIs), chemotherapy, and emerging targeted therapies. Drs. Scott Tagawa and Mary-Ellen Taplin discuss how disease volume, metastatic distribution, comorbidities, and patient goals inform individualized treatment selection. The program reviews key clinical trial evidence, the evolving role of germline and somatic testing, PTEN loss and AKT pathway targeting, and multidisciplinary strategies to manage adverse events and support quality of life during therapy.

*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.